Abstract |
Platelet aggregation and thrombosis play an important role in the onset of acute coronary events. Regardless of the stimulus for activation, platelet thrombus formation is ultimately regulated through the IIb/IIIa receptor complex. The effects of oral administration of xemilofiban, a non- peptide mimetic of the RGDF sequence of the IIb/IIIa receptor complex, on thrombus formation were evaluated in a canine model. Xemilofiban significantly reduced platelet deposition on severely damaged arterial wall. Platelet deposition was reduced at both low (13 +/- 1 from 56 +/- 18 x 10(6) platelets cm-2; P < 0.05) and high (23 +/- 2 from 111 +/- 21 x 10(6) platelets cm-2; P < 0.01) shear rates. Platelet deposition was reduced to a monolayer as seen by electron microscopy (platelet-vessel wall interaction). Therefore, the availability of an orally active IIb/IIIa antagonist for chronic use may have significant value in preventing thrombus formation in those clinical situations associated with severe arterial injury, such as atherosclerotic plaque disruption.
|
Authors | J J Badimon, B Meyer, L P Feigen, D A Baron, J H Chesebro, V Fuster, L Badimon |
Journal | European journal of clinical investigation
(Eur J Clin Invest)
Vol. 27
Issue 7
Pg. 568-74
(Jul 1997)
ISSN: 0014-2972 [Print] England |
PMID | 9263744
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzamidines
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- xemilofiban
|
Topics |
- Administration, Oral
- Animals
- Benzamidines
- Blood Flow Velocity
(drug effects)
- Carotid Arteries
(drug effects, ultrastructure)
- Carotid Artery Injuries
- Dogs
- Microscopy, Electron, Scanning
- Perfusion
- Platelet Aggregation
(drug effects)
- Platelet Aggregation Inhibitors
(administration & dosage, pharmacology)
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Thrombosis
(etiology, pathology, prevention & control)
|